دورية أكاديمية
أعرض في EDS

Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin.

التفاصيل البيبلوغرافية
العنوان: Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin.
المؤلفون: Bonatelli M; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil., Fornari IF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences Dr. Paulo Prata-FACISB, Barretos, Brazil., Bernécule PN; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences Dr. Paulo Prata-FACISB, Barretos, Brazil., Pinheiro LE; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences Dr. Paulo Prata-FACISB, Barretos, Brazil., Costa RFA; Barretos School of Health Sciences Dr. Paulo Prata-FACISB, Barretos, Brazil.; Research and Teaching Institute, Barretos Cancer Hospital, Barretos, Brazil., Longatto-Filho A; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal.; Laboratory of Medical Investigation (LIM-14), School of Medicine, University of São Paulo, São Paulo, Brazil., Junior JNA; Medical Oncology Department, Barretos Cancer Hospital, Barretos, Brazil., Silva ECA; Pathology Department, Barretos Cancer Hospital, Barretos, Brazil., Cárcano FM; Barretos School of Health Sciences Dr. Paulo Prata-FACISB, Barretos, Brazil.; Medical Oncology Department, Barretos Cancer Hospital, Barretos, Brazil., Pinheiro C; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences Dr. Paulo Prata-FACISB, Barretos, Brazil.
المصدر: Frontiers in oncology [Front Oncol] 2021 Jun 24; Vol. 11, pp. 682665. Date of Electronic Publication: 2021 Jun 24 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: Introduction: Cancer of unknown primary origin (CUP) is defined as metastatic cancer without identification of the primary site. Considering that only 15-20% of patients with CUP show a favorable outcome, identifying biomarkers may help improve the clinical management of patients who do not respond well to conventional therapies. In this context, the study of the metabolic profile of CUP may pave the way to establish new biomarkers and/or therapeutic targets; therefore, this study aimed to characterize the expression of metabolism-related proteins in CUP.
Materials and Methods: The expression of monocarboxylate transporters MCT1, MCT2 and MCT4, their chaperone CD147, the glucose transporter GLUT1 and the pH regulator CAIX was evaluated by immunohistochemistry in a series of 118 CUP patients, and the results were associated with the available clinicopathological information.
Results: The metabolism-related proteins MCT1, MCT4, CD147, GLUT1 and CAIX were expressed in a critical portion of the CUP (approximately 20 to 70%). MCT1 and CD147 were both more frequently expressed in cases with lymph nodes as metastasis dominant sites ( p = 0.001) as well as in samples from lymph nodes ( p < 0.001 and p = 0.002, respectively), while MCT1 expression was more frequently expressed in squamous cell carcinomas ( p = 0.045). A higher overall survival was observed in patients with tumors positive for GLUT1 and CAIX expression ( p = 0.011 and p = 0.041, respectively), but none of the proteins was an independent prognostic factor for overall survival in multivariable analysis.
Conclusion: The results suggest that a portion of CUPs present a hyperglycolytic phenotype, which is associated with higher overall survival.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Bonatelli, Fornari, Bernécule, Pinheiro, Costa, Longatto-Filho, Junior, Silva, Cárcano and Pinheiro.)
References: Biol Res. 2002;35(1):9-26. (PMID: 12125211)
Oncol Rev. 2019 Jul 22;13(2):403. (PMID: 31410246)
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180. (PMID: 28938091)
Pathol Oncol Res. 2012 Jul;18(3):721-8. (PMID: 22270867)
BMC Cancer. 2019 Dec 3;19(1):1173. (PMID: 31795962)
Curr Drug Metab. 2015;16(3):221-42. (PMID: 26504932)
Nat Rev Clin Oncol. 2020 Sep;17(9):541-554. (PMID: 32350398)
Cancer Epidemiol. 2019 Aug;61:139-141. (PMID: 31254795)
J Cell Physiol. 2005 Mar;202(3):654-62. (PMID: 15389572)
Nat Rev Clin Oncol. 2011 Nov 01;8(12):701-10. (PMID: 22048624)
Front Oncol. 2019 May 17;9:402. (PMID: 31165045)
J Gen Physiol. 1927 Mar 7;8(6):519-30. (PMID: 19872213)
J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
J Transl Med. 2014 Jan 06;12:2. (PMID: 24387319)
Eur J Cancer. 2002 Feb;38(3):409-13. (PMID: 11818207)
Cell Oncol. 2007;29(3):229-40. (PMID: 17452775)
Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
Metabolism. 2016 Feb;65(2):124-39. (PMID: 26773935)
J Biol Chem. 2005 Jul 22;280(29):27213-21. (PMID: 15917240)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Oncotarget. 2018 Apr 17;9(29):20386-20398. (PMID: 29755659)
Front Oncol. 2016 Mar 29;6:69. (PMID: 27066453)
Biomed Res Int. 2015;2015:242437. (PMID: 26779534)
Nat Rev Cancer. 2004 Nov;4(11):891-9. (PMID: 15516961)
J Transl Med. 2012 Jan 24;10:12. (PMID: 22272606)
Oncotarget. 2015 Dec 29;6(42):44403-21. (PMID: 26587828)
J Clin Invest. 2008 Dec;118(12):3835-7. (PMID: 19033652)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
BMC Cancer. 2016 Jul 26;16:535. (PMID: 27460659)
Mol Cancer Res. 2010 Nov;8(11):1547-57. (PMID: 20870738)
Ann Surg. 2016 Jan;263(1):138-45. (PMID: 25563886)
Mol Metab. 2020 Mar;33:48-66. (PMID: 31395464)
Front Endocrinol (Lausanne). 2019 Jun 28;10:417. (PMID: 31316469)
Clin Transl Oncol. 2013 Jan;15(1):55-64. (PMID: 23054751)
J Biomed Biotechnol. 2010;2010:427694. (PMID: 20454640)
Cell Rep. 2014 Jan 16;6(1):155-67. (PMID: 24388748)
Histol Histopathol. 2014 Dec;29(12):1511-24. (PMID: 24921258)
Cancer Metastasis Rev. 2007 Jun;26(2):299-310. (PMID: 17415526)
J Theor Biol. 2005 Aug 21;235(4):476-84. (PMID: 15935166)
J Transl Med. 2013 Aug 08;11:185. (PMID: 23927384)
EMBO J. 2000 Aug 1;19(15):3896-904. (PMID: 10921872)
Am J Pathol. 2001 Mar;158(3):905-19. (PMID: 11238039)
J Mol Med (Berl). 2016 Feb;94(2):155-71. (PMID: 26099350)
World J Gastroenterol. 2014 Sep 7;20(33):11780-7. (PMID: 25206282)
J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
PLoS One. 2018 Jul 2;13(7):e0199476. (PMID: 29965974)
Sci Rep. 2016 Sep 09;6:32804. (PMID: 27608940)
Cells. 2019 Dec 04;8(12):. (PMID: 31817208)
Clin Cancer Res. 2012 Jan 1;18(1):207-19. (PMID: 22016510)
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8. (PMID: 21930917)
Oncotarget. 2017 Mar 7;8(10):16875-16886. (PMID: 28187435)
Br J Cancer. 2020 Jan;122(2):157-167. (PMID: 31819195)
Tumour Biol. 2011 Oct;32(5):893-904. (PMID: 21598042)
J Cancer Res Clin Oncol. 2019 Apr;145(4):967-999. (PMID: 30825027)
Science. 1956 Feb 24;123(3191):309-14. (PMID: 13298683)
فهرسة مساهمة: Keywords: Warburg effect; cancer of unknown primary origin; glycolytic metabolism; immunohistochemistry; metabolic reprogramming
تواريخ الأحداث: Date Created: 20210712 Latest Revision: 20220424
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8264765
DOI: 10.3389/fonc.2021.682665
PMID: 34249728
قاعدة البيانات: MEDLINE
الوصف
تدمد:2234-943X
DOI:10.3389/fonc.2021.682665